Fortress Biotech (FBIO) Debt/Assets Ratio: History & Chart

Fortress Biotech, Inc.(FBIO)

Biotechnology · Bay Harbor Islands, FL

$2.05-0.04 (-1.91%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

FBIO Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

20.45%

DEBT TO ASSETS RATIO AVG TTM

31.29%

DEBT TO ASSETS RATIO AVG 3Y

48.41%

DEBT TO ASSETS RATIO AVG 5Y

38.98%

DEBT TO ASSETS RATIO AVG 10Y

36.75%

DEBT TO ASSETS RATIO AVG 15Y

30.76%

DEBT TO ASSETS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-34.63%

CURRENT VS 3Y AVG

-57.75%

CURRENT VS 5Y AVG

-47.53%

CURRENT VS 10Y AVG

-44.35%

CURRENT VS 15Y AVG

-33.50%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.09%

median of 874 covered companies

CURRENT VS SECTOR MEDIAN

+22627.76%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Fortress Biotech, Inc. (FBIO)	$68.10M	20.45%	31.29%	48.41%	38.98%
iBio, Inc. (IBIO)vs ›	$67.52M	0.02%	N/A	N/A	N/A
Spero Therapeutics, Inc. (SPRO)vs ›	$68.90M	0.04%	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.61M	0.33%	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$65.87M	0.51%	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$65.86M	0.19%	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.85M	0.00%	N/A	N/A	N/A
Tiziana Life Sciences Ltd (TLSA)vs ›	$70.63M	0.04%	N/A	N/A	N/A
Gain Therapeutics, Inc. (GANX)vs ›	$71.23M	0.04%	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$64.18M	0.08%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Fortress Biotech, Inc. (FBIO)

$68.10M

20.45%

31.29%

48.41%

38.98%

iBio, Inc. (IBIO)vs ›

$67.52M

0.02%

N/A

Spero Therapeutics, Inc. (SPRO)vs ›

$68.90M

0.04%

N/A

Champions Oncology, Inc. (CSBR)vs ›

$69.61M

0.33%

N/A

Gossamer Bio, Inc. (GOSS)vs ›

$65.87M

0.51%

N/A

Cingulate Inc. (CING)vs ›

$65.86M

0.19%

N/A

XBiotech Inc. (XBIT)vs ›

$65.85M

0.00%

N/A

Tiziana Life Sciences Ltd (TLSA)vs ›

$70.63M

0.04%

N/A

Gain Therapeutics, Inc. (GANX)vs ›

$71.23M

0.04%

N/A

Alps Group Inc (ALPS)vs ›

$64.18M

0.08%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Fortress Biotech, Inc. (FBIO)?

The debt to assets ratio for FBIO stock is 20.45%.

Is Fortress Biotech, Inc.'s debt to assets ratio high or low?

The debt to assets ratio of 20.45% is 48% below its 5-year average of 38.98%, near the low end of its 5-year range (15.03%–60.69%).

What is the TTM average debt to assets ratio for Fortress Biotech, Inc. (FBIO)?

The TTM average debt to assets ratio for FBIO stock is 31.29%.

What is the 3Y average debt to assets ratio for Fortress Biotech, Inc. (FBIO)?

The 3Y average debt to assets ratio for FBIO stock is 48.41%.

What is the 5Y average debt to assets ratio for Fortress Biotech, Inc. (FBIO)?

The 5Y average debt to assets ratio for FBIO stock is 38.98%.

What is the 10Y average debt to assets ratio for Fortress Biotech, Inc. (FBIO)?

The 10Y average debt to assets ratio for FBIO stock is 36.75%.

What is the 15Y average debt to assets ratio for Fortress Biotech, Inc. (FBIO)?

The 15Y average debt to assets ratio for FBIO stock is 30.76%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	20.45%
2026-03-31	15.03%
2025-12-31	40.04%
2025-09-30	37.65%
2025-06-30	43.29%
2025-03-31	41.69%
2024-12-31	52.67%
2024-09-30	56.28%
2024-06-30	60.69%
2024-03-31	53.85%
2023-12-31	50.54%
2023-09-30	49.12%
2023-06-30	46.71%
2023-03-31	46.52%
2022-12-31	43.27%
2022-09-30	38.76%
2022-06-30	32.69%
2022-03-31	29.10%
2021-12-31	18.91%
2021-09-30	20.73%
2021-06-30	20.69%
2021-03-31	25.07%
2020-12-31	26.72%
2020-09-30	27.77%
2020-06-30	43.29%
2020-03-31	50.69%
2019-12-31	50.85%
2019-09-30	52.58%
2019-06-30	49.05%
2019-03-31	55.27%
2018-12-31	56.39%
2018-09-30	37.46%
2018-06-30	35.48%
2018-03-31	32.48%
2017-12-31	27.04%
2017-09-30	25.96%
2017-06-30	18.79%
2017-03-31	15.58%
2016-12-31	16.53%
2016-09-30	18.84%
2016-06-30	22.38%
2016-03-31	19.93%
2015-12-31	19.74%
2015-09-30	27.10%
2015-06-30	28.13%
2015-03-31	26.95%
2014-12-31	16.16%
2014-09-30	16.71%
2014-06-30	15.93%
2014-03-31	15.30%
2013-12-31	13.54%
2013-09-30	13.88%
2013-06-30	21.47%
2013-03-31	32.28%
2012-12-31	30.22%
2012-09-30	29.31%
2012-06-30	1.95%
2012-03-31	4.16%
2011-12-31	3.21%
2011-09-30	2.80%

DATE

DEBT TO ASSETS RATIO

2026-06-30

20.45%

2026-03-31

15.03%

2025-12-31

40.04%

2025-09-30

37.65%

2025-06-30

43.29%

2025-03-31

41.69%

2024-12-31

52.67%

2024-09-30

56.28%

2024-06-30

60.69%

2024-03-31

53.85%

2023-12-31

50.54%

2023-09-30

49.12%

2023-06-30

46.71%

2023-03-31

46.52%

2022-12-31

43.27%

2022-09-30

38.76%

2022-06-30

32.69%

2022-03-31

29.10%

2021-12-31

18.91%

2021-09-30

20.73%

2021-06-30

20.69%

2021-03-31

25.07%

2020-12-31

26.72%

2020-09-30

27.77%

2020-06-30

43.29%

2020-03-31

50.69%

2019-12-31

50.85%

2019-09-30

52.58%

2019-06-30

49.05%

2019-03-31

55.27%

2018-12-31

56.39%

2018-09-30

37.46%

2018-06-30

35.48%

2018-03-31

32.48%

2017-12-31

27.04%

2017-09-30

25.96%

2017-06-30

18.79%

2017-03-31

15.58%

2016-12-31

16.53%

2016-09-30

18.84%

2016-06-30

22.38%

2016-03-31

19.93%

2015-12-31

19.74%

2015-09-30

27.10%

2015-06-30

28.13%

2015-03-31

26.95%

2014-12-31

16.16%

2014-09-30

16.71%

2014-06-30

15.93%

2014-03-31

15.30%

2013-12-31

13.54%

2013-09-30

13.88%

2013-06-30

21.47%

2013-03-31

32.28%

2012-12-31

30.22%

2012-09-30

29.31%

2012-06-30

1.95%

2012-03-31

4.16%

2011-12-31

3.21%

2011-09-30

2.80%

Debt to Assets Ratio: 20.45%

FBIO Debt to Assets Ratio

FBIO Average Debt to Assets Ratio Chart

FBIO Current vs Average Debt to Assets Ratio Chart

FBIO Debt to Assets Ratio Metrics

FBIO Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

FBIO Debt to Assets Ratio History

Related Metrics